CHAMPAIGN, Ill. — Light-activated proteins can help normalize dysfunction within cells and could be used as a treatment for diseases such as cancer or mitochondrial diseases, new research suggests.
Researchers from the University of Cincinnati, the University of Illinois Urbana-Champaign and the University at Buffalo published the results of their study in the journal Nature Communications.
The research centers on the functions of mitochondria, organelles within a cell that act as the cell’s “power plant” and source of energy. Hundreds of mitochondria are constantly coming together – a process called fusion – and dividing into smaller parts – a process known as fission – to stay balanced in healthy cells, said study leader Jiajie Diao, a professor of cancer biology at UC. But when mitochondria are not functioning properly, there is an imbalance of this process of fission and fusion.
This imbalance can lead to a number of mitochondrial diseases, including neurodegenerative diseases like dementia and certain cancers.
Previous research found that another organelle within cells called a lysosome can play a role in mitochondria fission. When a mitochondria comes in contact with a lysosome, the lysosome can act like a pair of scissors and cut the mitochondria into smaller pieces.
The current research focused on jump-starting the fission process by bringing the lysosomes and mitochondria together within cells. This was accomplished using a technique known as optogenetics, which can precisely control specific cell functions using light.
“Many proteins in plants are light-sensitive, informing plants whether it is day or night. Optogenetics borrows these light-sensitive proteins from plants and uses them in animal cells,” said study coauthor Kai Zhang, a biochemistry professor at Illinois who developed the optogenetic tools for controlling mitochondria and lysosomes with blue light. “By attaching such proteins to organelles, one can use light to control the interaction between them, such as mitochondria and lysosomes shown in this work.”
The researchers attached two separate proteins to mitochondria and lysosomes within stem cells. When stimulated by blue light, the proteins naturally bind to each other to form one new protein, which also brings the mitochondria and lysosome into contact. Once they are brought together, the lysosome can cut the mitochondria, achieving fission.
“We found that this technique can recover mitochondrial function,” Diao said. “Some of the cells even can go back to normal. This proves that just by using some simple light stimulation, we can at least partially recover the mitochondrial function of the cell.”
This technique could be especially useful for patients with dramatically oversized mitochondria that need to be divided into smaller pieces to achieve normal cell function, Diao said. The technique also could be aimed at cancer cells, continually separating the mitochondria into smaller pieces until they can no longer function.
“Eventually the cancer cell will be killed because mitochondria are their energy,” Diao said. “Without normal functional mitochondria, all of the cancer cells will be killed.”
Editor’s notes: This news release is adapted from content provided by the University of Cincinnati. For more information, contact Tim Tedeschi, Public Information Officer, University of Cincinnati, firstname.lastname@example.org; or Kai Zhang, University of Illinois, email@example.com.
Since the proteins are activated by light, the optogenetic technique allows for a more targeted approach to specific cells, Diao said. Only cells exposed to the light are affected, meaning healthy cells nearby do not have their mitochondria unbalanced through the technique.
There are currently other processes that can be used to induce mitochondrial fission, but Diao said the optogenetic method is safer since it does not involve chemicals or toxic agents.
“What we have is actually the natural process, we’re just making it faster,” Diao said. “So it’s not like a chemical or a therapy or a radiotherapy, where you need to reduce the side effects.”
Diao’s team is using the same technique to encourage fusion to address issues when mitochondria are unbalanced because they are too small and not coming together as they should within cells.
Further research from Zhang’s lab also will include developing new optogenetic systems working with different colors of light, including green, red and infrared, since a longer wavelength will be needed to penetrate human tissue.
“We would like to further expand the toolbox by introducing multicolor optogenetic systems to give us multiple ways to control how organelles behave and interact,” Zhang said. “For instance, one color makes organelles come together, while the other color forces them apart. This way, we can precisely control their interactions.”
From the current research using human stem cells, the team hopes to progress to animal models on the way to eventually testing the technique in humans through clinical trials. At the same time, other research groups are studying the use of magnetic fields and acoustic vibrations – instead of light – to accomplish similar results, Diao said.
The National Institutes of Health supported this work.